For Immediate Release
Chapel Hill, NC - March 18, 2015 - Rho, a contract research organization (CRO) focused on bringing new products to market through a full range of product development services, has recently been honored by Life Science Leader magazine as a leader in the CRO industry. The 4th CRO Leadership Awards highlight top CROs as identified by decision makers in pharmaceutical and biopharmaceutical companies.
"At Rho, innovation, quality, great people, and a team culture are part of our core values, which have allowed our company to succeed,"� said Russ Helms, chief executive officer, Rho. "It is an honor to be recognized by Life Science Leader, and by our customers, with this award."�
Awardees were determined based on industry-leading market research from Nice Insight. Respondents from big pharma, mid-sized and specialty pharma, emerging pharma, biotech, and emerging biotech companies were polled, and scores were calculated in the perception categories of quality, productivity, reliability, innovation and regulatory record. The top 10 percent of companies in each category were recognized as winners of a CRO Leadership Award.
Life Science Leader launched the awards in 2011 to help the magazine's pharmaceutical and biopharmaceutical subscribers find and vet reputable CRO partners. These unique industry awards are given based only on the feedback of companies using CRO services.
To learn more about Rho, please visit www.rhoworld.com.
Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For more than 25 years, Rho has been a trusted partner to some of the industry's leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. Please follow us on Twitter.